Chosa Oncology

0.86 SEK

+17.81 %

Less than 1K followers

CHOSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+17.81 %

-15.69 %

-9.47 %

-14.00 %

-4.44 %

+31.45 %

-36.98 %

-96.14 %

-93.18 %

Chosa Oncology is a Swedish-Danish biotechnology company that develops solutions for personalized cancer treatment with a focus on diagnostics and drug formulation. The company targets healthcare providers and research actors and works internationally with partners and clinical projects. Chosa Oncology was founded in 2022 and is headquartered in Lund, Sweden.

Market cap

75.56M SEK

Turnover

699.18 SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

26/2

2026

Annual report '25

27/5

2026

General meeting '26

All

Press releases

ShowingAll content types

Press release2/6/2026, 2:17 PM

Chosa Oncology AB: Riktad emission i CHOSA Oncology AB registrerad på Bolagsverket

Press release1/23/2026, 7:33 AM

Chosa Oncology AB: Precision Oncology patent application targeting Platinum Response and Immunotherapy Synergy

Press release1/23/2026, 7:33 AM

Chosa Oncology AB: CHOSA - Patentansökan inom precisionsonkologi med fokus på platinarespons och synergier med immunterapi

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release1/19/2026, 7:53 AM

Chosa Oncology AB: CHOSA Oncology AB resolves on a directed issue of units of initially approximately SEK 7.3 million

Regulatory press release1/19/2026, 7:53 AM

Chosa Oncology AB: CHOSA Oncology AB beslutar om riktad emission av units om initialt cirka 7,3 MSEK

Regulatory press release12/11/2025, 1:12 PM

Chosa Oncology AB: CHOSA - Marknaden dubbleras nu för Platin-DRP® som förutsäger totalöverlevnad hos patienter med lungcancer genom NanoString-data

Regulatory press release12/11/2025, 1:12 PM

Chosa Oncology AB: CHOSA - The market now doubles for Platin-DRP®, which predicts overall survival in lung cancer patients based on NanoString data

Regulatory press release11/13/2025, 7:30 AM

Chosa Oncology AB: CHOSA Oncology AB - Kvartalsrapport juli-sept 2025.

Press release11/10/2025, 9:00 AM

Chosa Oncology AB: CHOSA - Platinum chemotherapy is the backbone of PD-1/PD-L1-based lung cancer therapy

Press release11/10/2025, 9:00 AM

Chosa Oncology AB: CHOSA - Platinabaserad kemoterapi är ryggraden i PD-1/PD-L1-baserad lungcancerbehandling

Press release10/20/2025, 10:00 AM

Chosa Oncology AB: CHOSA presenterade om carboplatin-respons-prediktorn hos bröstcancerpatienter på ESMO-konferensen

Press release10/20/2025, 10:00 AM

Chosa Oncology AB: CHOSA's presented data on the carboplatin response predictor in breast cancer patients on the ESMO conference

Press release10/7/2025, 1:28 PM

Chosa Oncology AB: CHOSA vinner 2025 års Jiangning International Entrepreneurship Contest (Greater Shanghai region), Kina

Press release10/7/2025, 1:28 PM

Chosa Oncology AB: CHOSA Wins 2025 Jiangning International Entrepreneurship Contest (Greater Shanghai region), China

Regulatory press release9/30/2025, 11:03 AM

Chosa Oncology AB: CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer

Regulatory press release9/30/2025, 11:03 AM

Chosa Oncology AB: CHOSA presenterar positiva resultat från en klinisk studie i samarbete med ETOP/EORTC kring platin-prediktor i lungcancer

Regulatory press release8/28/2025, 6:30 AM

Chosa Oncology AB: CHOSA Oncology AB - Kvartalsrapport april-juni 2025.

Press release8/8/2025, 6:00 AM

Chosa Oncology AB: CHOSA's presents data on the carboplatin response predictor in breast cancer patients on the annual ESMO conference

Press release8/8/2025, 6:00 AM

Chosa Oncology AB: CHOSA presenterar data om carboplatin-responsprediktorn för bröstcancerpatienter på den årliga ESMO-kongressen

Regulatory press release8/1/2025, 12:29 PM

Chosa Oncology AB: Chosa Oncologys teckningsoptioner av serie TO 2 tas upp till handel

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.